Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Status:
Completed
Trial end date:
2021-09-16
Target enrollment:
Participant gender:
Summary
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a
single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy
to see what the body does to the drug (pharmacokinetics) and what the drug does to the body
(pharmacodynamics), and to compare if these effects are similar to those observed in adults.